Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Coformycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA known ✓ | P00813 | 4/20 | 0.68 |
| ▸ | AMPD3 | Q01432 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Coformycin SCHEMBL8373037 | 1.00 | ADA (0.68) | ADAAMPD3ALDH1A1TP53HTT | |
| Coformycin SCHEMBL13697294 | 1.00 | ADA (0.68) | ADAAMPD3ALDH1A1TP53HTT | |
| Coformycin SCHEMBL13697497 | 1.00 | ADA (0.68) | ADAAMPD3ALDH1A1TP53HTT | |
| Coformycin SCHEMBL7796895 | 1.00 | ADA (0.68) | ADAAMPD3ALDH1A1TP53HTT | |
| SCHEMBL10792647 | 0.90 | ADA (0.55) | ADAAMPD3ALDH1A1TP53HTT | |
| SCHEMBL8371414 | 0.90 | ADA (0.55) | ADAAMPD3ALDH1A1TP53HTT | |
| SCHEMBL7790217 | 0.90 | ADA (0.55) | ADAAMPD3ALDH1A1TP53HTT | |
| SCHEMBL10705678 | 0.90 | ADA (0.55) | ADAAMPD3ALDH1A1TP53HTT | |
| SCHEMBL13111762 | 0.90 | ADA (0.58) | ADAAMPD3ALDH1A1TP53HTT | |
| SCHEMBL13697498 | 0.87 | ADA (0.53) | ADAAMPD3ALDH1A1TP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 731 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4086250-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2024-12-11 | — | — | EP | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| US-20230413828-A1 | BIOHERBICIDES FOR CONTROLLING ONE OR MORE PLANT SPECIES | AGROSPHERES, INC. | 2023-12-28 | — | — | US | claimed |
| EP-4247160-A1 | BIOHERBICIDES FOR CONTROLLING ONE OR MORE PLANT SPECIES | Agrospheres, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| US-20220333137-A1 | METHODS AND PRODUCTS FOR PRODUCING ENGINEERED MAMMALIAN CELL LINES WITH AMPLIFIED TRANSGENES | PRECISION BIOSCIENCES, INC. (US) | 2022-10-20 | — | — | US | claimed |
| EP-4045504-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | Ai-biopharma (FR) | 2022-08-24 | — | — | EP | claimed |
| CN-114901657-A | Antiviral and liver-targeting drugs | 人工智能生物制药公司 | 2022-08-12 | — | — | CN | claimed |
| WO-2022108944-A1 | BIOHERBICIDES FOR CONTROLLING ONE OR MORE PLANT SPECIES | AGROSPHERES, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| WO-2021074443-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2021-04-22 | — | — | WO | claimed |
| US-5679648-A | ADMINISTERING TO MAMMALS; INCUBATION WITH CELLS, TISSUES, FOODS | THE UNIVERSITY HOSPITAL (US) | 1997-10-21 | — | — | US | claimed |
| US-5663155-A | PURINE NUCLEOSIDE AND DEAMINASE INHIBITOR | THE UNIVERSITY HOSPITAL (US) | 1997-09-02 | — | — | US | claimed |
| WO-1996020010-A1 | COMBINATION FOR REDUCING ANTIMICROBIAL RESISTANCE USING A METHYLATION INHIBITOR IN COMBINATION WITH AN ANTIBIOTIC | ORIDIGM CORPORATION (US) | 1996-07-04 | — | — | WO | claimed |
| WO-1994017809-A1 | ADENOSINE DEAMINASE INHIBITOR THERAPIES | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | claimed |
| EP-0509470-A2 | Therapeutical compositions having anti-HIV activity consisting of 2',3'-didesoxyadenosine and substances inhibiting adenosine deaminase | REPLA CHEMICAL LTD. (LI) | 1992-10-21 | — | — | EP | claimed |
| EP-0262125-A4 | AICA riboside for the prophylactic treatment of diseases with restricted blood flow. | GRUBER HARRY EDWARD | 1989-07-26 | — | — | EP | claimed |
| EP-0262125-A1 | AICA riboside for the prophylactic treatment of diseases with restricted blood flow. | GRUBER HARRY EDWARD | 1988-04-06 | — | — | EP | claimed |
| WO-1987005807-A1 | A METHOD OF INCREASING ADENOSINE EXCRETION | GRUBER HARRY EDWARD | 1987-10-08 | — | — | WO | claimed |
| US-4151347-A | ION EXCHANGE RESINS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1979-04-24 | — | — | US | claimed |
| US-3959257-A | BACTERICIDES | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1976-05-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | ADA 4323/4885AMPD3 2838/4885ALDH1A1 2758/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | ADA 3229/4885AMPD3 2358/4885ALDH1A1 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.